Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Akari Therapeutics PLC | AKTX | NASDAQ | Depository Receipt |
Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded ![]() |
|
---|---|---|---|---|---|---|---|---|
0.01 | 0.52% | 1.92 | 1.95 | 1.87 | 1.93 | 1.91 | 17:29:53 |
Bid Price | Ask Price | Spread | Spread % | News | |
---|---|---|---|---|---|
1.88 | 1.96 | 0.08 | 4.08% | - | - |
Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume |
---|---|---|---|---|
523 | 127,696 | 1.90 | 243,000 | 418,995 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:38:03 | 2 | 1.88 | USD |
Akari Therapeutics Financials
Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | |
---|---|---|---|---|---|
40.34M | 21.01M | -16.47M | -1.39 | - | 19.69M |
Dividends Per Share | Dividend Yield | ||||
---|---|---|---|---|---|
- | - | 0.00% | - | 0.10% |
News Akari Therapeutics
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
AKTX Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom. |